We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (4346)2/16/2017 11:21:17 AM
From: richardred  Read Replies (1) | Respond to of 7026
Adding to some ANIK today. Although Mr. market was most likely looking for more. I didn't think earnings were that bad to warrant today's slide. Interga still in the buying mood. This before the close of MY DSCI.

Integra LifeSciences To Buy J & J Codman Neurosurgery Business For $1.045 Bln
( - Integra LifeSciences Holdings Corp. ( IART ) announced it has made a binding offer to acquire the Johnson & Johnson Codman Neurosurgery business for a price of $1.045 billion in cash. Integra expects the transaction to be accretive to adjusted EPS by at least $0.22 in the first full year after closing and increasing thereafter, and to GAAP EPS by the end of the third year.

Integra LifeSciences expects the acquisition to also accelerate the path to achieving the company's targets of $2 billion in revenue and 30% adjusted EBITDA margin. Integra expects the Codman Neurosurgery revenue to experience some initial disruption in the first year of the combination, and to then grow 3% to 6% longer term.

Codman Neurosurgery is a part of Depuy Synthes Companies of Johnson & Johnson. It offers a portfolio of devices focused on advanced hydrocephalus, neuro-critical care and operative neurosurgery. The acquired products generated approximately $370 million in revenue during 2016 with an EBITDA margin of about 31%.

For comments and feedback: contact

To: richardred who wrote (4346)3/19/2018 11:12:20 AM
From: richardred  Read Replies (1) | Respond to of 7026
New buy today MDWD -MEDIWOUND

The company said it has been approached. Basically this is still a R &D company in wound care. I'm going to make a small bet. This based upon a big Past wound care winner I had in Derma Science.

P.S. - MediWound ( MDWD ): gets merger approach, Q4 loss beats views